Rainbow Coral Corp (RBCC) 0.0309 $RBCC
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
Business Wire - Thu Jun 26, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage.
RBCC to Increase Investment in 3D Bioprinting Innovation
Business Wire - Tue Mar 25, 9:18AM CDT
As demand for new cellular research innovations continues to soar worldwide, Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), is increasing its investment in the marketing and development of a breakthrough 3D bioprinting technology.
RBCC: Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry
Business Wire - Thu Mar 06, 4:00AM CST
A new research publication lists Rainbow Coral Corp. (OTCBB: RBCC) Nano3D Biosciences (n3D) as a leading stakeholder in an industry forecast to be worth $10 billion by 2030.
RBCC Increases Foothold in 3D Bioprinting Market
Business Wire - Wed Feb 26, 6:49AM CST
With analysts around the globe predicting incredible growth in the 3D printing sector in the coming years, Rainbow Coral Corp. (OTCBB: RBCC) announced today that it will extend its investment position in Nano3D Biosciences (n3D), a company on the cutting edge of the 3D bioprinting revolution.
RBCC: New Innovations Spur Demand for 3D Printing in Medicine
Business Wire - Thu Feb 20, 4:00AM CST
As Rainbow Coral Corp. (OTCBB: RBCC) works to market and develop an innovative new 3D bioprinting system, new 3D printing innovations are generating massive new demand for the technology from patients and doctors alike in the medical industry.
New Product Puts RBCC on Leading Edge of Organ Regeneration Research
Business Wire - Tue Feb 18, 4:00AM CST
The 3D printing of functional human organs could be a reality within the next decade, and Rainbow Coral Corp. (OTCBB: RBCC) is helping to lead the bioprinting revolution now underway.
RBCC Seeks Out Capital Partners for 3D Bioprinting Expansion
Business Wire - Thu Feb 06, 4:00AM CST
Rainbow Bioscience, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it is seeking out new capital partners to help expand marketing and streamline development on the BiO Assay, a 3D bioprinting system poised to potentially revolutionize the drug development industry.
RBCC: 3D Bioprinting Tech Ushers in Future of Medicine
Business Wire - Mon Feb 03, 7:40AM CST
The BiO Assay, a magnetic 3D bioprinting system being marketed and developed by Rainbow Coral Corp. (OTCBB: RBCC) and joint venture partner Nano3D Biosciences (n3D), is the first designed specifically for rapid, high-volume drug screening--ushering in an exciting new era in medicine.
RBCC Develops Innovations in White-Hot 3D Bioprinting Sector
Business Wire - Mon Jan 27, 3:00AM CST
As global demand for new innovations in the booming 3D printing industry grows exponentially by the day, Rainbow Coral Corp. (OTCBB: RBCC) is preparing to capitalize with groundbreaking new products for the 3D marketplace.
RBCC Explores New Contacts in Personalized Medicine and Drug Delivery
Business Wire - Wed Jan 22, 6:53AM CST
Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that the company's executive leadership is now pursuing potentially lucrative partnerships with contacts made at last week's Biotech Showcase in San Francisco.
RBCC Moves to the Front Lines of the 3D Bioprinting Revolution
Business Wire - Mon Jan 20, 4:00AM CST
Rainbow Coral Corp. (OTCBB: RBCC) is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).
RBCC Prepares Big Push Into Booming 3D Bioprinting Market
Business Wire - Thu Jan 16, 4:00AM CST
Thanks to new technology innovations pioneered by its partners at Nano3D Biosciences (n3D), Rainbow Coral Corp. (OTCBB: RBCC) is planning a major push into the skyrocketing 3D bioprinting market in 2014.
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase
Business Wire - Wed Jan 15, 3:59AM CST
Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Therakine, Ltd., presented its new novel drug-delivery technology at one of the world's largest and most important gatherings of life sciences investors this week at the Biotech Showcase in San Francisco.
RBCC Opens Talks with Top Innovators at Major Biotech Conference
Business Wire - Tue Jan 14, 7:56AM CST
The executive leadership of Rainbow Coral Corp. (OTCBB:RBCC), a biotechnology company, is spending its week meeting with potential partners and innovators in San Francisco at one of the largest and most important biotechnology conferences in the world.
RBCC Partner n3D Commercializes New 3D Bioprinting Technology
Business Wire - Mon Jan 13, 4:52AM CST
Rainbow Coral Corp.'s (OTCBB: RBCC) joint venture partner, Nano3D Biosciences (n3D), has developed the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening, and the global market potential for the device points to very bright future for the company.
RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest
Business Wire - Wed Sep 18, 4:00AM CDT
As part of their ongoing efforts to publicize the breakthrough capabilities of the new Bio-Assembler 3D cell culturing system, Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) will reanimate last year's highly successful MAD Scientist Contest to help introduce a new crop of bio-researchers to the device.
Scientific Journal Boosts Bio-Assembler's Market Potential
Business Wire - Thu Sep 12, 4:00AM CDT
Another high-profile piece of reporting on the Bio-Assembler, a 3-D cell culturing system being developed and marketed by Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D), was published today: this time in Nature Protocols, an online journal of laboratory protocols for bench researchers.
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
RBCC 3D Bioprinting Partner Awarded Prestigious Grant
Business Wire - Thu Jul 31, 5:54AM CDT
The joint venture of Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D), moved significantly closer to its funding goals this week thanks to a prestigious research grant from the National Institutes of Health.
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
Business Wire - Wed Jul 02, 4:00AM CDT
Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.
RBCC: New Research Could Massively Expand Market for Addiction Therapy Technology
Business Wire - Thu Jun 26, 4:00AM CDT
As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug's potential could soon dramatically expand the drug's market and usage.
RBCC to Increase Investment in 3D Bioprinting Innovation
Business Wire - Tue Mar 25, 9:18AM CDT
As demand for new cellular research innovations continues to soar worldwide, Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), is increasing its investment in the marketing and development of a breakthrough 3D bioprinting technology.
RBCC: Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry
Business Wire - Thu Mar 06, 4:00AM CST
A new research publication lists Rainbow Coral Corp. (OTCBB: RBCC) Nano3D Biosciences (n3D) as a leading stakeholder in an industry forecast to be worth $10 billion by 2030.
RBCC Increases Foothold in 3D Bioprinting Market
Business Wire - Wed Feb 26, 6:49AM CST
With analysts around the globe predicting incredible growth in the 3D printing sector in the coming years, Rainbow Coral Corp. (OTCBB: RBCC) announced today that it will extend its investment position in Nano3D Biosciences (n3D), a company on the cutting edge of the 3D bioprinting revolution.
RBCC: New Innovations Spur Demand for 3D Printing in Medicine
Business Wire - Thu Feb 20, 4:00AM CST
As Rainbow Coral Corp. (OTCBB: RBCC) works to market and develop an innovative new 3D bioprinting system, new 3D printing innovations are generating massive new demand for the technology from patients and doctors alike in the medical industry.
New Product Puts RBCC on Leading Edge of Organ Regeneration Research
Business Wire - Tue Feb 18, 4:00AM CST
The 3D printing of functional human organs could be a reality within the next decade, and Rainbow Coral Corp. (OTCBB: RBCC) is helping to lead the bioprinting revolution now underway.
RBCC Seeks Out Capital Partners for 3D Bioprinting Expansion
Business Wire - Thu Feb 06, 4:00AM CST
Rainbow Bioscience, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), announced today that it is seeking out new capital partners to help expand marketing and streamline development on the BiO Assay, a 3D bioprinting system poised to potentially revolutionize the drug development industry.
RBCC: 3D Bioprinting Tech Ushers in Future of Medicine
Business Wire - Mon Feb 03, 7:40AM CST
The BiO Assay, a magnetic 3D bioprinting system being marketed and developed by Rainbow Coral Corp. (OTCBB: RBCC) and joint venture partner Nano3D Biosciences (n3D), is the first designed specifically for rapid, high-volume drug screening--ushering in an exciting new era in medicine.
RBCC Develops Innovations in White-Hot 3D Bioprinting Sector
Business Wire - Mon Jan 27, 3:00AM CST
As global demand for new innovations in the booming 3D printing industry grows exponentially by the day, Rainbow Coral Corp. (OTCBB: RBCC) is preparing to capitalize with groundbreaking new products for the 3D marketplace.
RBCC Explores New Contacts in Personalized Medicine and Drug Delivery
Business Wire - Wed Jan 22, 6:53AM CST
Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that the company's executive leadership is now pursuing potentially lucrative partnerships with contacts made at last week's Biotech Showcase in San Francisco.
RBCC Moves to the Front Lines of the 3D Bioprinting Revolution
Business Wire - Mon Jan 20, 4:00AM CST
Rainbow Coral Corp. (OTCBB: RBCC) is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).
RBCC Prepares Big Push Into Booming 3D Bioprinting Market
Business Wire - Thu Jan 16, 4:00AM CST
Thanks to new technology innovations pioneered by its partners at Nano3D Biosciences (n3D), Rainbow Coral Corp. (OTCBB: RBCC) is planning a major push into the skyrocketing 3D bioprinting market in 2014.
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase
Business Wire - Wed Jan 15, 3:59AM CST
Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Therakine, Ltd., presented its new novel drug-delivery technology at one of the world's largest and most important gatherings of life sciences investors this week at the Biotech Showcase in San Francisco.
RBCC Opens Talks with Top Innovators at Major Biotech Conference
Business Wire - Tue Jan 14, 7:56AM CST
The executive leadership of Rainbow Coral Corp. (OTCBB:RBCC), a biotechnology company, is spending its week meeting with potential partners and innovators in San Francisco at one of the largest and most important biotechnology conferences in the world.
RBCC Partner n3D Commercializes New 3D Bioprinting Technology
Business Wire - Mon Jan 13, 4:52AM CST
Rainbow Coral Corp.'s (OTCBB: RBCC) joint venture partner, Nano3D Biosciences (n3D), has developed the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening, and the global market potential for the device points to very bright future for the company.
RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest
Business Wire - Wed Sep 18, 4:00AM CDT
As part of their ongoing efforts to publicize the breakthrough capabilities of the new Bio-Assembler 3D cell culturing system, Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner Nano3D Biosciences (n3D) will reanimate last year's highly successful MAD Scientist Contest to help introduce a new crop of bio-researchers to the device.
Scientific Journal Boosts Bio-Assembler's Market Potential
Business Wire - Thu Sep 12, 4:00AM CDT
Another high-profile piece of reporting on the Bio-Assembler, a 3-D cell culturing system being developed and marketed by Rainbow Coral Corp. (OTCBB:RBCC) and Nano3D Biosciences (n3D), was published today: this time in Nature Protocols, an online journal of laboratory protocols for bench researchers.
